|
1
|
Beierle EA, Ma X, Stewart J, Nyberg C,
Trujillo A, Cance WG and Golubovskaya VM: Inhibition of focal
adhesion kinase decreases tumor growth in human neuroblastoma. Cell
Cycle. 9:1005–1015. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rössler J, Monnet Y, Farace F, Opolon P,
Daudigeos-Dubus E, Bourredjem A, Vassal G and Geoerger B: The
selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor
activity in human neuroblastoma xenografts. Int J Cancer.
128:2748–2758. 2011. View Article : Google Scholar
|
|
3
|
Lee S, Qiao J, Paul P and Chung DH:
Integrin β1 is critical for gastrin-releasing peptide
receptor-mediated neuroblastoma cell migration and invasion.
Surgery. 154:369–375. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hayashi M, Okabe K, Kato K, Okumura M,
Fukui R, Fukushima N and Tsujiuchi T: Differential function of
lysophosphatidic acid receptors in cell proliferation and migration
of neuroblastoma cells. Cancer Lett. 316:91–96. 2012. View Article : Google Scholar
|
|
6
|
Gencer N, Sonmez F, Demir D, Arslan O and
Kucukislamoglu M: Synthesis, structure-activity relationships and
biological activity of new isatin derivatives as tyrosinase
inhibitors. Curr Top Med Chem. 14:1450–1462. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bürger S, Yafai Y, Bigl M, Wiedemann P and
Schliebs R: Effect of VEGF and its receptor antagonist SU-5416, an
inhibitor of angiogenesis, on processing of the β-amyloid precursor
protein in primary neuronal cells derived from brain tissue of
Tg2576 mice. Int J Dev Neurosci. 28:597–604. 2010. View Article : Google Scholar
|
|
8
|
Lane ME, Yu B, Rice A, Lipson KE, Liang C,
Sun L, Tang C, McMahon G, Pestell RG and Wadler S: A novel
cdk2-selective inhibitor, SU9516, induces apoptosis in colon
carcinoma cells. Cancer Res. 61:6170–6177. 2001.PubMed/NCBI
|
|
9
|
Uchiyama H, Sowa Y, Wakada M, Yogosawa M,
Nakanishi R, Horinaka M, Shimazaki C, Taniwaki M and Sakai T:
Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to
methotrexate in human T-cell leukemia Jurkat cells. Cancer Sci.
101:728–734. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moshinsky DJ, Bellamacina CR, Boisvert DC,
Huang P, Hui T, Jancarik J, Kim SH and Rice AG: SU9516: Biochemical
analysis of cdk inhibition and crystal structure in complex with
cdk2. Biochem Biophys Res Commun. 310:1026–1031. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mohammadi M, McMahon G, Sun L, Tang C,
Hirth P, Yeh BK, Hubbard SR and Schlessinger J: Structures of the
tyrosine kinase domain of fibroblast growth factor receptor in
complex with inhibitors. Science. 276:955–960. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hou L, Ju C, Zhang J, Song J, Ge Y and Yue
W: Antitumor effects of Isatin on human neuroblastoma cell line
(SH-SY5Y) and the related mechanism. Eur J Pharmacol. 589:27–31.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song J, Hou L, Ju C, Zhang J, Ge Y and Yue
W: Isatin inhibits proliferation and induces apoptosis of SH-SY5Y
neuroblastoma cells in vitro and in vivo. Eur J Pharmacol.
702:235–241. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
Relative Gene Expression Data Using Real-Time Quantitative PCR and
the 2− ΔΔCT Method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
15
|
Baldin V, Lukas J, Marcote MJ, Pagano M
and Draetta G: Cyclin D1 is a nuclear protein required for cell
cycle progression in G1. Genes Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu HF, Lai KC, Hsu SC, Lin HJ, Kuo CL,
Liao CL, Yang JS and Chung JG: Involvement of matrix
metalloproteinases on the inhibition of cells invasion and
migration by emodin in human neuroblastoma SH-SY5Y cells. Neurochem
Res. 34:1575–1583. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hodge DR, Hurt EM and Farrar WL: The role
of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer.
41:2502–2512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Molinari M: Cell cycle checkpoints and
their inactivation in human cancer. Cell Prolif. 33:261–274. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sankpal UT, Abdelrahim M, Connelly SF, Lee
CM, Madero-Visbal R, Colon J, Smith J, Safe S, Maliakal P and Basha
R: Small molecule tolfenamic acid inhibits PC-3 cell proliferation
and invasion in vitro and tumor growth in orthotopic mouse model
for prostate cancer. Prostate. 72:1648–1658. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Comstock CE, Revelo MP, Buncher CR and
Knudsen KE: Impact of differential cyclin D1 expression and
localisation in prostate cancer. Br J Cancer. 96:970–979. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu S, Mott RT, Fry EA, Taneja P, Kulik G,
Sui G and Inoue K: Cooperation between Dmp1 loss and cyclin D1
overexpression in breast cancer. Am J Pathol. 183:1339–1350. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zaravinos A, Lambrou GI, Volanis D,
Delakas D and Spandidos DA: Spotlight on differentially expressed
genes in urinary bladder cancer. PLoS One. 6:e182552011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsioras K, Papastefanaki F, Politis PK,
Matsas R and Gaitanou M: Functional Interactions between
BM88/Cend1, Ran-binding protein M and Dyrk1B kinase affect cyclin
D1 levels and cell cycle progression/exit in mouse neuroblastoma
cells. PLoS One. 8:e821722013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Matthay KK, Villablanca JG, Seeger RC,
Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT,
Brodeur GM, et al: Treatment of high-risk neuroblastoma with
intensive chemotherapy, radiotherapy, autologous bone marrow
transplantation and 13-cis-retinoic acid. Children's cancer group.
N Engl J Med. 341:1165–1173. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Monclair T, Brodeur GM, Ambros PF, Brisse
HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK,
Nuchtern JG, et al: The International neuroblastoma risk group
(INRG) staging system: An INRG task force report. J Clin Oncol.
27:298–303. 2009. View Article : Google Scholar :
|
|
26
|
Steeg PS and Theodorescu D: Metastasis: A
therapeutic target for cancer. Nat Clin Pract Oncol. 5:206–219.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Paz H, Pathak N and Yang J: Invading one
step at a time: The role of invadopodia in tumor metastasis.
Oncogene. 33:4193–4202. 2014. View Article : Google Scholar :
|
|
28
|
Hua H, Li M, Luo T, Yin Y and Jiang Y:
Matrix metalloproteinases in tumorigenesis: An evolving paradigm.
Cell Mol Life Sci. 68:3853–3868. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chaudhary AK, Singh M, Bharti AC, Asotra
K, Sundaram S and Mehrotra R: Genetic polymorphisms of matrix
metalloproteinases and their inhibitors in potentially malignant
and malignant lesions of the head and neck. J Biomed Sci.
17:102010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
DeClerck YA, Perez N, Shimada H, Boone TC,
Langley KE and Taylor SM: Inhibition of invasion and metastasis in
cells transfected with an inhibitor of metalloproteinases. Cancer
Res. 52:701–708. 1992.PubMed/NCBI
|
|
31
|
Liu H, Jiang C, Xiong C and Ruan J: DEDC,
a new flavonoid induces apoptosis via a ROS-dependent mechanism in
human neuroblastoma SH-SY5Y cells. Toxicol In Vitro. 26:16–23.
2012. View Article : Google Scholar
|
|
32
|
Kamran MZ, Patil P and Gude RP: Role of
STAT3 in cancer metastasis and translational advances. Biomed Res
Int. 2013:4218212013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Walker SR, Xiang M and Frank DA: Distinct
roles of STAT3 and STAT5 in the pathogenesis and targeted therapy
of breast cancer. Mol Cell Endocrinol. 382:616–621. 2014.
View Article : Google Scholar
|
|
34
|
Overall CM and López-Otín C: Strategies
for MMP inhibition in cancer: Innovations for the post-trial era.
Nat Rev Cancer. 2:657–672. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhuang L, Lee CS, Scolyer RA, McCarthy SW,
Zhang XD, Thompson JF and Hersey P: Mcl-1, Bcl-XL and Stat3
expression are associated with progression of melanoma whereas
Bcl-2, AP-2 and MITF levels decrease during progression of
melanoma. Mod Pathol. 20:416–426. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang T, Niu G, Kortylewski M, Burdelya L,
Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola
D, et al: Regulation of the innate and adaptive immune responses by
Stat-3 signaling in tumor cells. Nat Med. 10:48–54. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bollrath J, Phesse TJ, von Burstin VA,
Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T,
Canli O, Schwitalla S, et al: gp130-mediated Stat3 activation in
enterocytes regulates cell survival and cell-cycle progression
during colitis-associated tumorigenesis. Cancer Cell. 15:91–102.
2009. View Article : Google Scholar : PubMed/NCBI
|
